Market capitalization | $5.84m |
Enterprise Value | $2.46m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.45 |
P/S ratio (TTM) P/S ratio | 1.08 |
P/B ratio (TTM) P/B ratio | 0.89 |
Revenue growth (TTM) Revenue growth | 1.39% |
Revenue (TTM) Revenue | $5.41m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Biomerica, Inc.:
1 Analyst has issued a forecast Biomerica, Inc.:
May '24 |
+/-
%
|
||
Revenue | 5.41 5.41 |
1%
1%
|
|
Gross Profit | 0.61 0.61 |
36%
36%
|
|
EBITDA | -5.99 -5.99 |
13%
13%
|
EBIT (Operating Income) EBIT | -6.37 -6.37 |
12%
12%
|
Net Profit | -5.98 -5.98 |
16%
16%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. It focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other Foreign. The company was founded in September 1971 and is headquartered in Irvine, CA.
Head office | United States |
CEO | Zackary Irani |
Employees | 64 |
Founded | 1971 |
Website | www.biomerica.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.